Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
6,244,123
-
Share change
-
+2,534,932
-
Total reported value
-
$69,990,576
-
Put/Call ratio
-
49%
-
Price per share
-
$11.21
-
Number of holders
-
73
-
Value change
-
+$28,799,797
-
Number of buys
-
51
-
Number of sells
-
20
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q2 2020
As of 30 Jun 2020,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
73 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,244,123 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, RAYMOND JAMES & ASSOCIATES, ABNER HERRMAN & BROCK LLC, RENAISSANCE TECHNOLOGIES LLC, WINTON GROUP Ltd, Nuveen Asset Management, LLC, and Phoenix Holdings Ltd..
This page lists
73
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.